Drug profile · INN
mometasone furoate
ELOCON
mometasone furoate (ELOCON) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: implantation. Current US regulatory status: approved.
Drug details — mometasone furoate
- US status
- approved
- Class
- —
- Route
- IMPLANTATION
- Patents
- 0
- Programs
- 7
- Data quality
- 0.89
Quick answer
mometasone furoate (ELOCON) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: implantation. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mometasone furoate?
mometasone furoate (ELOCON) is a glucocorticoid receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: implantation. Current US regulatory status: approved.
What is the brand name for mometasone furoate?
ELOCON is a marketed brand name for mometasone furoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mometasone furoate?
mometasone furoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.